Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: FTSE +0.3%, DAX +0.2%, CAC +0.4%

Oct 26 ,2026

  • Synopsis

    • European equity markets set to open broadly higher following last week's losses when the Stoxx Europe 600 closed down (1.39%) for the week. European markets spent the week under pressure from French fiscal stress, energy spikes and growing doubts over the AI investment boom.

    • Some good news for France after Moody's held France's credit rating steady. The sovereign debt rating was maintained at Aa3. Treasury yields pulling back amid rally in French OAT futures. Oil pulling back from one-month high as expectations of a resumption of US-Iran conflict continue to build. President Trump repeated he is nearing decision on whether to resume hostilities unless Iran agrees to a deal. Diplomacy remains at a standstill with Iran sticking to its demands for reopening Strait of Hormuz and refusing to discuss nuclear file. Lot of discussion about economic ramifications with Iran threatening targets across Middle East if it is attacked.

    • In other developments, pre-market trading in Brazilian assets signaling volatile Monday session following Lula's surprise election victory.

    • Central bank decisions also in focus this week with Fed, ECB and BoJ updates this week, though all three are expected to leave policy unchanged. RBNZ and BOC both expected to hike.

    • European macro data releases out today include Germany Oct business climate - Ifo, Spain Sep PPI, UK Oct distributive trades - CBI, Sweden Sep PPI. Finland Sep PPI comes in at +9.8% y/y vs consensus +7.8% and prior +7.3%.

    • In central banks, ECB's Elderson speech at 7:00CET at Finance and Biodiversity Day at 17th meeting of the Conf. of the Parties to the CBD (COP17). Bundesbank's Lienenkämper speech at 10:00CET at Conf. on the Regulation of Securities Institutions in the Capital Markets Union. Bundesbank's Köhler-Geib panellist at 18:50CET at AI Week Frankfurt. Bank of Italy's Angelini opening remarks at Africa Growth and Opportunity: Research in Action 2026 Conf (AGORA 26). Chancellor Merz begins a visit to Singapore, Japan, and South Korea (through Fri). In the UK, immigration kicks-off MP's topics before they debate the performance of the Royal Mail and the emerging risks of advanced AI. Committee topics include COP31 at 14:45GMT. EU's Kallas attends the E5 defence ministers' meeting

    • A relatively quiet Monday for earnings, with Galp (GALP.PL) among the main mover, beating Q3 expectations and raising FY26 EBITDA and operating cash flow guidance. Galp and Moeve also confirmed they have ended talks on a potential downstream combination On further M&A, Frasers Group (FRAS.LN) confirmed it has crossed the 50% ownership threshold in Hugo Boss (BOSS.GR), a significant development that brings consolidation effects onto Frasers' balance sheet. Barclays (BARC.LN) attracted weekend speculation in the Mail on Sunday suggesting its low valuation could make it a takeover target. . In healthcare, a busy ESMO congress is generating newsflow, with AstraZeneca (AZN.LN) presenting multiple positive datasets across bladder cancer and gastric cancer, while Amgen (AMGN) reported strong survival data for Imdelltra in small cell lung cancer. Notable broker moves include Telefonica (TEF.SM) cut to Underweight at JPMorgan, Munich Re (MUV2.GR) downgraded at BNP Paribas Exane.

    • Note Austrian markets closed for National Day.

  • Politics/Macro/World News

    • France

      • France avoids downgrade from Moody's in boost for Macron's government; maintains sovereign debt rating at Aa3 (FT , Le Monde )

      • French presidential hopeful Philippe slips in new poll (POLITICO)

      • French protest groups demand more rallies as Macron faces tough choices

    • Iran

      • Trump nearing decision on whether to strike Iran:

    • EU

      • EU weighs mirroring Donald Trump in securing critical minerals (FT)

      • Euro-Zone Slowdown Will Help Keep ECB Rates on Hold for Now (BBG )

    • UK

      • Poorest pensioners set to be shielded from income tax in budget (Times )

    • Germany

      • Germany To Tap Ukrainian Tech With Missile Purchase (FT )

    • Brazil

      • Lula wins Brazil presidential election

      • Brazilian markets brace for steep losses following Lula's surprise election victory:

    • Serbia

      • Celebrations in Serbia after veteran ruler Vučić loses election to student-led protest movement (BBC )

  • Top company news

    • Earnings/updates

      • PNL.NA (PostNL) -- reports Q3 revenue €768M vs year-ago €762M; confirms FY26 outlook

      • SPSN.SW Swiss Prime Site targets Funds from operations (FFO I) per share to grow by more than 15% by 2030; raises 2026 guidance -- CMD

      • GALP.PL (Galp Energia SGPS) -- reports Q3 RCA net income €682M vs consensus €634M; rasies FY26 RCA EBITDA and OCF guidance

        • Also reporting today

          • Earnings: Nordics: Alleima (ALLEI.SS)

          • Southern Europe: Sogefi (SGF.IM), Iberpapel Gestion (IBG.SM)

          • UK: Bioventix (BVXP.LN)

        • Trading Update:

          • Benelux: MotorK (MTRK.NA)

          • France: Verimatrix (VMX.FP)

          • Southern Europe: Puig Brands (PUIG.SM), Distribuidora Internacional De Alimentacion (DIA.SM)

    • M&A

      • GALP.PL (Galp) -- and Moeve confrim they ended negotiations on a potential downstream combination

      • BARC.LN (Barclays) -- Given its low share price, someone may try to buy Barclays - Mail on Sunday

      • AAL.LN (Anglo American) -- MMG offers EC new remedies with regards to purchase of Anglo American's nickel

      • BOSS.GR (Hugo Boss), FRAS.LN (Frasers Group) -- provides update on investment in Hugo Boss; completes 50% threshold transaction, includes details & consolidation effects

      • business - Bloomberg

      • KNEBV.FH (Kone) -- seeking to retain TK Elevator operations in Spain, Portugal - FT

      • MUX.GR (Mutares SE & Co KGaA) -- divests Stuart to Quiver; terms undisclosed

      • SIKA.SW (Sika Group) -- Sika acquires Dubai-based manufacturer of waterproofing membranes Duproof; price not disclosed

      • ENDUR.NO (Endúr) -- subsidiary BMO to acquire 100% of the shares in Notech AS

      • ELV.AU (Elevra Lithium) -- completes sale of rights and interests in Ewoyaa lithium project to Zhejiang Huayou Cobalt

      • 603799.CH (Zhejiang Huayou Cobalt) -- completes acquisition of Atlantic Lithium Singapore from Piedmont Lithium

      • EVR.GA (I. Kloukinas-I. Lappas Construction & Commerce) -- CrediaBank and Evropi merger expected to complete on or ~30-Oct; Evropi's shares last day of trading on Euronext Athens is 26-Oct (post EU close 23-Oct)

      • Veritas Capital exploring sale of Chromalloy at potential $10B+ valuation -- Bloomberg

    • Healthcare

      • AMGN (Amgen) -- announces IMDELLTRA in combination with IMFINZI reduced risk of death by 58% in first-line extensive stage small cell lung cancer

      • ABBV (AbbVie) -- announces FDA approval of subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active Crohn's Disease

      • AZN.LN (AstraZeneca) -- announces perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

      • AZN.LN (AstraZeneca) -- presents, publishes results from SAFFRON Phase III trial of TAGRISSO

      • AZN.LN (AstraZeneca) -- reports results from Phase III CLARITY-Gastric01 trial of Sone-Ve at ESMO

      • REGN (Regeneron) -- presents new longer-term data on Libtayo at ESMO

      • NOVN.SW (Novartis) -- Transcript Intelligence: Novartis at ACTRIMS & ECTRIMS Meeting

      • NOVO.B.DC (Novo Nordisk) -- FDA approves Awiqli for pediatric patients 10 years and older

      • ROP.SW (Roche Holding) -- presents interim Phase III data showing Sefaxersen significantly reduced proteinuria in people with IgA Nephropathy (IgAN)

      • ROP.SW (Roche Holding) -- Genentech presents, publishes pivotal results from Phase III Krascendo 1 study of divarasib

      • BAYN.GR (Bayer AG) -- Bayer presents late-breaking data on darolutamide at ESMO

      • GMAB.DC (Genmab) -- presents updated follow-up analyses from trial of petosemtamab at ESMO

      • IDIA.SW (Idorsia) -- to pursue new development program for daridorexant in ASD; program details expected in H1 of 2027 following discussions with health authorities

      • NANO.FP (Nanobiotix) -- presents updated results from Study 1100 of JNJ-1900 (NBTXR3) at ESMO

      • HNSA.SS (Hansa Biopharma) -- announces data from the European post-authorization efficacy and safety (PAES) study of Idefirix (imlifidase)

      • BINV.SS (BioInvent International) -- BioInvent International's BI-1808 and KEYTRUDA induce durable responses in heavily pretreated platinum-resistant ovarian cancer

    • Other

      • BORR.NO (Borr Drilling) -- Prospector 5 drilling rig sinks; five people remain unaccounted for

      • BP to make $350M payment to Louisiana to resolve 2015 Deepwater Horizon Economic Damages Settlement

      • Estimated weekend box office revenues in US, Canada $98.2M, +29.6% y/y - Box Office Mojo

      • RF.FP (Eurazeo) -- board appoints Christophe Bavière as Chairman of the Executive board and CEO

  • Key rating changes

    • Upgrades

      • AVIO.IM (Avio) -- to buy from hold at Berenberg

      • HIAB.FH (Hiab) -- to buy from hold at SEB

      • NHY.NO (Norsk Hydro) -- to hold from sell at ABG Sundal Collier

      • NHY.NO (Norsk Hydro) -- to hold from sell at SEB

      • ORNBV.FH (Orion) -- to buy from hold at Jefferies

    • Downgrades

      • DB1.GR (Deutsche Börse) -- to neutral from outperform at Oddo

      • NHY.NO (Norsk Hydro) -- to neutral from buy at Goldman Sachs

      • SAAB.B.SS (Saab) -- to hold from buy at DNB Carnegie

      • SCA.B.SS (Svenska Cellulosa) -- to hold from buy at Pareto

      • SCA.B.SS (Svenska Cellulosa) -- to hold from buy at Jefferies

      • MUV2.GR (Munich Re) -- to neutral from outperform at BNP Paribas Exane

      • TEF.SM (Telefonica) -- to underweight from neutral at JPMorgan

    • Initiations

      • BC.IM (Brunello Cucinelli) -- outperform at CLSA

  • Data

    • Nikkei (0.80%) to 62189.65

    • Hang Seng +0.51% to 23210.30

    • Shanghai Composite +0.00% to 3690.50

    • S&P futures +6.0 vs prior close of 7659.8

    • €-$ (0.0007) or (0.06%) to 1.1217

    • $-¥ (0.05) or (0.03%) to 156.93

    • €-¥ (0.18) or (0.10%) to 176.02

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

    • BNY.com Terms of Use Privacy Cookie Notice Manage Cookies Disclaimer CUSIP Disclaimer

    • ©  2025 The Bank of New York Corporation. Depositary Receipt business and services are conducted through The Bank of New York.